Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 2,730,000 2,152,300 1,937,200 3,916,300 3,105,900 3,491,300 3,395,100 3,345,700 2,885,600 3,432,400 2,072,200 1,437,900 2,193,700 1,573,000 1,992,200 2,208,200 1,617,800 1,384,800 1,045,500 1,708,500
Marketable securities 8,114,800 7,761,300 6,990,500 5,043,400 4,636,400 3,530,400 4,171,300 3,704,900 2,809,100 2,355,200 1,838,600 2,065,900 1,393,300 1,452,900 1,152,000 1,795,200 1,596,500 1,493,100 1,624,200 1,523,900
Accounts receivable, net 5,667,300 5,584,500 5,121,300 5,118,600 5,328,700 5,548,300 5,161,400 4,839,000 6,036,500 5,452,000 6,998,600 4,173,000 4,114,700 4,039,500 2,811,300 2,933,200 2,672,200 2,660,000 2,455,900 2,305,200
Inventories 2,580,500 2,562,000 2,507,700 2,424,700 2,401,900 2,412,200 2,218,500 1,991,500 1,951,300 2,053,800 1,983,900 2,164,700 1,916,600 1,801,600 1,640,900 1,480,900 1,415,500 1,344,300 1,317,200 1,208,800
Prepaid expenses and other current assets 386,600 574,700 366,300 406,200 411,200 446,400 583,600 424,900 332,400 482,000 444,300 213,600 160,800 230,600 263,800 226,600 387,100 226,900 208,200 182,200
Current assets 19,479,200 18,634,800 16,923,000 16,909,200 15,884,100 15,428,600 15,529,900 14,306,000 14,014,900 13,775,400 13,337,600 10,055,100 9,779,100 9,097,600 7,860,200 8,644,100 7,689,100 7,109,100 6,651,000 6,928,600
Marketable securities 5,396,500 5,778,500 6,327,200 6,066,600 6,591,800 5,968,600 6,415,900 7,084,000 6,838,000 5,631,300 3,900,300 3,543,700 3,135,600 2,875,100 2,587,600 3,236,400 3,256,800 3,112,600 2,884,600 2,339,800
Property, plant, and equipment, net 4,146,400 4,006,100 3,922,600 3,880,900 3,763,000 3,704,200 3,637,700 3,556,400 3,482,200 3,395,700 3,358,500 3,262,600 3,221,600 3,138,300 3,031,400 2,944,600 2,890,400 2,771,400 2,676,600 2,612,800
Intangible assets, net 1,038,600 1,017,200 953,000 928,700 915,500 804,100 — — — — — — — — — — — — — —
Deferred tax assets 2,575,400 2,316,800 2,138,500 1,924,900 1,723,700 1,452,100 1,352,400 1,140,300 876,900 723,200 746,600 765,100 858,900 804,200 774,000 771,200 824,200 808,300 821,600 829,300
Other noncurrent assets 444,100 409,900 393,200 349,600 336,400 320,200 269,900 262,000 222,800 145,900 142,900 145,700 168,100 168,800 175,500 161,200 144,700 137,900 139,800 144,300
Noncurrent assets 13,601,000 13,528,500 13,734,500 13,150,700 13,330,400 12,249,200 11,675,900 12,042,700 11,419,900 9,896,100 8,148,300 7,717,100 7,384,200 6,986,400 6,568,500 7,113,400 7,116,100 6,830,200 6,522,600 5,926,200
Total assets 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Regeneron Pharmaceuticals Inc. current assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Property, plant, and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Regeneron Pharmaceuticals Inc. property, plant, and equipment, net increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc. noncurrent assets decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Regeneron Pharmaceuticals Inc. total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Regeneron Pharmaceuticals Inc. cash and cash equivalents increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Marketable securities Amount of investment in marketable security, classified as current. Regeneron Pharmaceuticals Inc. marketable securities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Regeneron Pharmaceuticals Inc. accounts receivable, net increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Regeneron Pharmaceuticals Inc. inventories increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.